Janssen has launched a new partnership with Bupa Home Healthcare to support patients with chronic genotype-1 hepatitis C using Incivo (telaprevir).
The MYINCIVO Support Programme aims to increase adherence awareness through SMS text reminders, health coaching and advice from healthcare professionals.
Dr Peter Barnes, Medical Director at Janssen, says the programme has been created to help with the “challenging” and “significant commitment” needed by patients using hep C treatments.
During the development of the support programme, Janssen worked closely with Bupa Home Healthcare, healthcare professionals and patient support groups.
The confidential personalised programmes have been established to complement existing care provided by a patient’s specialist nurse or doctor and helps maintain continuity of care and support.
Patients have access to confidential advice and support to help them adhere to prescription guidelines and help maintain their health, stay motivated and be in control whilst undertaking treatment. Patients’ partners, carers and family members can also access the tailor-made programmes.
Confidential advice and support is available 24 hours a day, seven days a week, to support patients, carers or family members when they require assistance.
Dr Mehmood Syed, Medical Director at Bupa Home Healthcare, said that increasing “better health outcomes” for patients “is at the heart of this programme”.
“We want to empower patients so that they have more control over their health as well as provide them with dedicated medical expertise and support when they need it,” he said.
It’s estimated there are between 216,000 and 466,000 individuals who are chronically infected with hepatitis C in the UK.
Janssen’s Incivo received approval for use in combination with peginterferon alfa and ribavirin from the European Commission in September 2011.
Before the introduction of protease inhibitors, of which Incivo is the latest, treatment for genotype-1 chronic hep C cleared the virus in only around half of patients, leaving the other half without a successful outcome after 12 months of treatment.
Incivo has been shown in clinical trials to be more effective than standard treatment options in all genotype-1 patient types. In fact, the addition of Incivo to existing current standard treatment cleared the virus in a significantly greater number of patients who were previously untreated.